Correspondence

New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors

Bookmark and Share
E Q Klug, F J Raal

Authors' affiliations

E Q Klug, Netcare Sunninghill and Sunward Park hospitals, Gauteng Province, South Africa; School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Division of Cardiology, Charlotte Maxeke Johannesburg Academic Hospital, South Africa

F J Raal, Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Division of Endocrinology and Metabolism, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Full Text

PDF (64KB)

Cite this article

South African Medical Journal 2020;110(11):1059. DOI:10.7196/SAMJ.2020.v110i11.15191

Article History

Date submitted: 2020-10-28
Date published: 2020-10-28

Article Views

Abstract views: 1455
Full text views: 967

Comments on this article

*Read our policy for posting comments here